{"request_id":"3f8307f22ca7ae1fe8d310b6362f0e0a","results":{"ticker":"GILD","name":"Gilead Sciences Inc","market":"stocks","locale":"us","primary_exchange":"XNAS","type":"CS","active":true,"currency_name":"usd","cik":"0000882095","composite_figi":"BBG000CKGBP2","share_class_figi":"BBG001S6Y1X7","market_cap":120899380000.0,"phone_number":"(650) 574-3000","address":{"address1":"333 LAKESIDE DR","city":"FOSTER CITY","state":"CA","postal_code":"94404"},"description":"Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).","sic_code":"2836","sic_description":"BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)","ticker_root":"GILD","homepage_url":"https://www.gilead.com","total_employees":18000,"list_date":"1992-01-22","branding":{"logo_url":"https://api.polygon.io/v1/reference/company-branding/Z2lsZWFkLmNvbQ/images/2024-10-01_logo.svg","icon_url":"https://api.polygon.io/v1/reference/company-branding/Z2lsZWFkLmNvbQ/images/2024-10-01_icon.png"},"share_class_shares_outstanding":1244990000,"weighted_shares_outstanding":1246000000,"round_lot":100},"status":"OK"}
